Market Overview

Japanese Government to Provide Funding for Unoprostone Isopropyl Phase 3 Clinical Trial for Retinitis Pigmentosa


Sucampo Pharmaceuticals (NASDAQ: SCMP) today announced that the
Japan Science and Technology Agency (JST) has adopted unoprostone
isopropyl ophthalmic solution .15% in the Adaptable and Seamless
Technology Transfer Program. As part of this program, R-Tech Ueno,
Sucampo's development partner, has signed an agreement for unoprostone
isopropyl with the JST in which the Japanese government shall provide
the majority of funding* for Phase 3 clinical development costs for
unoprostone isopropyl for retinitis pigmentosa (RP). Sucampo is
co-developing unoprostone isopropyl with R-Tech Ueno and may file for
FDA approval of the product for retinitis pigmentosa (RP) in the future
assuming the successful trials.

A form of unoprostone isopropyl, trade name RESCULA®, is

See full press release

Posted-In: Earnings News Guidance Contracts Management Global


Related Articles (SCMP)

View Comments and Join the Discussion!